FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Reg Review Period on Pharmings Ruconest

[ Price : $8.95]

Federal Register Notice: FDA determines the regulatory review period for Pharming Groups Ruconest for patent extension purposes 3...

Reg Review Determination on Celegenes Cerdelga

[ Price : $8.95]

Federal Register Notice: FDA determines the regulatory review period for Celgenes Cerdelga (eliglustat) for patent extension purpo...

Draft Guide on Pediatric Clinical Trials

[ Price : $8.95]

Federal Register Notice: FDA makes available a draft guidance entitled E11(R1) Addendum: Clinical Investigation of Medicinal Produ...

5 Off-label Communication Hearing Themes

[ Price : $8.95]

Mintz Levin attorneys summarize five important themes from an FDA hearing on appropriate regulation of off-label communication.

CP Pharmaceuticals Inspection Found CGMP Issues

[ Price : $8.95]

FDA warns CP Pharmaceuticals about CGMP violations in its manufacture of finished pharmaceuticals.

Guidance on Drug Metabolite Safety Testing

[ Price : $8.95]

FDA posts a guidance on Safety Testing of Drug Metabolites that provides recommendations to industry on when and how to identify a...

Petition Seeks Change on Probiotic Quantitative Labeling

[ Price : $8.95]

The International Probiotics Association petitions FDA asking that it amend its to require the quantitative amount of probiotic in...

FDA Untitled Letter on Unapproved Biologic

[ Price : $8.95]

FDA sends Antera Therapeutics an untitled letter due to promotional claims on the companys Web site that make Aralyte Starter Kit ...

Guide Revises Recommendations on Donor Eligibility for Tissues/Cells

[ Price : $8.95]

Federal Register Notice: FDA makes available a guidance entitled Revised Recommendations for Determining Eligibility of Donors of ...

Sanofi Discontinuing TheraCys Bladder Cancer Therapy

[ Price : $8.95]

Sanofi Pasteur decides to discontinue making TheraCys (BCG live attenuated), indicated for treating non-muscle invasive bladder ca...